Breast Milk Sugars and Solid Food Fibres Jointly Sculpt the Infant Gut During Weaning

The first year of life is a race between microbes. From birth, the infant gut is colonized by bacteria shaped almost entirely by one food source: mother's milk. Then weaning begins, solid foods arrive, and the microbial landscape has to reorganize almost from scratch. A new study published in Nature Communications by Yunjeong So, Maher Abou Hachem, and colleagues at the Technical University of Denmark and the University of Copenhagen reveals a surprisingly clean rule governing that reorganization: the bacteria that win during weaning are precisely those that can digest both human milk oligosaccharides and the dietary fibres found in solid food.

Human Milk Oligosaccharides Prime the Infant Gut Microbiome

Human milk oligosaccharides, or HMOs, are complex carbohydrates that make up the third most abundant solid component of breast milk. Infants cannot digest them directly; instead, HMOs function as prebiotics that feed beneficial gut bacteria, especially Bifidobacterium species. Exclusively breastfed infants are accordingly dominated by HMO-utilising Bifidobacterium, which ferment these sugars and crowd out less beneficial microbes. What has been less clear is how that community prepares for the dramatic dietary shift that weaning represents. The DTU-Copenhagen team found that even before solid foods are introduced, the pre-weaning microbiome already harbours bacteria capable of growing on common dietary fibres, suggesting the groundwork for the adult microbiome is laid earlier than previously appreciated.

Dual HMO-Fibre Utilisation Selects Weaning Gut Bacteria

The central finding is that dual utilisation of HMOs and dietary fibres is the metabolic hallmark of the weaning gut microbiome. Bacteria that can do both hold a decisive competitive advantage: they are sustained by breast milk sugars during exclusive breastfeeding, then pivot seamlessly to plant-derived fibres once solid foods appear. The team identified a conserved protein apparatus in butyrate-producing Firmicutes, including Roseburia intestinalis, a well-characterised degrader of the dietary fibre xylan, that enables these bacteria to take up fucosylated type 1 HMO blocks via specific ATP-binding cassette (ABC) importers. This is not a coincidence of metabolic versatility; it looks like a deliberate evolutionary adaptation to the sequentially changing nutritional environment of the infant gut. As early gut microbiome composition has documented links to immune development and long-term metabolic health, understanding what drives healthy succession during weaning carries real clinical weight.

How Seven Mother-Infant Dyads Revealed a Conserved Mechanism

The study's credibility rests on a multi-pronged design. The team sampled faeces from seven mother-infant dyads at three timepoints: pre-weaning, early weaning, and late weaning, generating 306 enrichment cultures and 108 metagenomic analyses. They also analyzed 137 maternal isolates to map HMO utilisation in the maternal gut, and enriched maternal faecal samples on HMOs and mucin to assess microbial growth patterns. The poor growth of maternal isolates on mucin, and comparatively strong growth on HMOs, supports the authors' inference that HMO-utilisation pathways in adult gut bacteria are a legacy of early-life selection rather than an incidental biochemical capability. This combination of culture-based enrichment and metagenomics allowed the team to connect molecular mechanisms, specifically the ABC importer apparatus, to community-level dynamics across weaning stages.

Open Questions About Scale and Longer-Term Microbiome Trajectories

Seven dyads is a small cohort, and the authors are transparent about the scope of the study. Whether the dual HMO-fibre utilisation mechanism generalises across populations with different weaning practices, HMO profiles, or starting microbiome compositions remains to be tested. Questions also persist about whether formula-fed infants supplemented with human-identical milk oligosaccharides would show the same microbial selection dynamics, given that baseline microbial composition differs substantially between breastfed and formula-fed infants. The study tracks infants only through late weaning; longer longitudinal data would be needed to confirm that the dual utilisers identified here persist and shape the adult microbiome in meaningful ways. Cell-culture and enrichment models, while powerful for isolating mechanisms, also do not fully reproduce the complexity of the living gut.

Butyrate Producers and a New Framework for Early-Life Microbial Succession

The practical implications branch in two directions. First, the identification of a conserved protein apparatus enabling butyrate-producing Firmicutes to utilise HMOs suggests a molecular target for microbiome-informed interventions during weaning: probiotic strains engineered or selected for dual utilisation capacity could potentially smooth the weaning transition. Second, the finding reframes how researchers should think about HMO supplementation in infant formula. Rather than asking only whether HMOs promote Bifidobacterium in early infancy, the relevant question is whether they also prime the gut for the adult-associated butyrate producers that arrive during weaning. Butyrate itself matters: it serves as the primary energy source for colonocytes and plays regulatory roles in gut barrier integrity and inflammation. The authors describe the dual utilisation machinery as reflecting bacterial adaptation to both infant and adult gut environments, a characterisation that positions weaning not as a disruption to be minimized but as a programmed selection event that early nutrition can either support or undermine. That framing, if it holds up across larger cohorts, could shift how clinicians and formula manufacturers think about the weaning window entirely.